C4 Therapeutics (CCCC) EBITDA Margin (2019 - 2026)
C4 Therapeutics' quarterly EBITDA Margin came in at 414.52% in Q1 2026, down 5071.0% year-on-year from 8.34% in Q1 2025, and down 121.92% quarter-over-quarter from 186.78% in Q4 2025.
C4 Therapeutics has reported EBITDA Margin for 8 years, with the latest figure at 414.52% in Q1 2026.
- For the quarter ending Q1 2026, EBITDA Margin fell 5071.0% year-over-year to 414.52%; the trailing twelve-month figure through Mar 2026 stood at 298.96% (down 4042.0% YoY), and the FY2025 full-year result was 292.09%, up 337.0% from the prior year.
- EBITDA Margin for Q1 2026 stood at 414.52%, down from 186.78% in the prior quarter.
- The five-year high for EBITDA Margin was 148.06% in Q2 2024, with the low at 1322.3% in Q2 2023.
- Average EBITDA Margin over 5 years is 556.17%, with a median of 414.52% recorded in 2026.
- Year-over-year, EBITDA Margin tumbled 117727 bps in 2022 and jumped 117424 bps in 2024.
- Tracing CCCC's EBITDA Margin over 5 years: stood at 1258.34% in 2022, then increased by 17 bps to 1041.92% in 2023, then jumped by 35 bps to 675.58% in 2024, then soared by 72 bps to 186.78% in 2025, then slumped by 122 bps to 414.52% in 2026.
- The last three EBITDA Margin figures came in at 414.52% (Q1 2026), 186.78% (Q4 2025), and 285.39% (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | -6.43% |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 38.10% |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 18.35% |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 17.24% |
| 10 | C4 Therapeutics | 561.03 Mn | 325.36 Mn | - | -414.52% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -414.52% |
| Dec 31, 2025 | -186.78% |
| Sep 30, 2025 | -285.39% |
| Jun 30, 2025 | -403.73% |
| Mar 31, 2025 | -363.80% |
| Dec 31, 2024 | -675.58% |
| Sep 30, 2024 | -154.74% |
| Jun 30, 2024 | -148.06% |
| Mar 31, 2024 | -941.56% |
| Dec 31, 2023 | -1,041.92% |
| Sep 30, 2023 | -236.33% |
| Jun 30, 2023 | -1,322.30% |
| Mar 31, 2023 | -880.90% |
| Dec 31, 2022 | -1,258.34% |
| Sep 30, 2022 | -485.43% |
| Jun 30, 2022 | -204.88% |
| Mar 31, 2022 | -450.68% |
| Dec 31, 2021 | -81.07% |
| Sep 30, 2021 | -291.40% |
| Jun 30, 2021 | -230.60% |
| Mar 31, 2021 | -283.84% |
| Dec 31, 2020 | -263.74% |
| Sep 30, 2020 | -258.38% |
| Jun 30, 2020 | -111.63% |
| Mar 31, 2020 | -174.77% |
| Dec 31, 2019 | -122.05% |
| Sep 30, 2019 | -188.09% |